Director Treco Douglas A Granted 13,000 Stock Options

On June 5, 2026, Douglas A. Treco, a director at CRISPR Therapeutics AG, was granted 13,000 stock options with an exercise price of $51.84 per share. These options are exercisable for Common Shares. The options will vest in 12 equal monthly installments starting June 30, 2026, with the final vesting occurring on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting, provided Treco continues his service to the company. The options expire on June 5, 2036. This transaction is reported on Form 4.